Taking it up a NOTCH: a novel subgroup of ACC is identified

por Ferrarotto, Renata, Heymach, John V.
Publicado 2017

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer

por Hong, Lingzhi, Zhang, Jianjun, Heymach, John V., Le, Xiuning
Publicado 2021

Predictive biomarkers in precision medicine and drug development against lung cancer

por Fang, Bingliang, Mehran, Reza J, Heymach, John V, Swisher, Stephen G
Publicado 2015

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib

por Tchekmedyian, Nishan, Paxton, Bill, Lebel, Francois, Keossayan, Lena, Heymach, John V.
Publicado 2020

Antibody-drug conjugates in lung cancer: dawn of a new era?

por Coleman, Niamh, Yap, Timothy A., Heymach, John V., Meric-Bernstam, Funda, Le, Xiuning
Publicado 2023

8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition

por Kearney, Alper Y., Fan, You-Hong, Giri, Uma, Saigal, Babita, Gandhi, Varsha, Heymach, John V., Zurita, Amado J.
Publicado 2015

Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.

por Tu, Huakang, Heymach, John V., Wen, Chi-Pang, Ye, Yuanqing, Pierzynski, Jeanne A., Roth, Jack A., Wu, Xifeng
Publicado 2016

miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer()

por Vo, Dat T., Karanam, Narasimha Kumar, Ding, Lianghao, Saha, Debabrata, Yordy, John S., Giri, Uma, Heymach, John V., Story, Michael D.
Publicado 2019

T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy

por Frank, Meredith L., Lu, Kaylene, Erdogan, Can, Han, Yi, Hu, Jian, Wang, Tao, Heymach, John V., Zhang, Jianjun, Reuben, Alexandre
Publicado 2023

Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus

por James, Michael A., Wen, Weidong, Wang, Yian, Byers, Lauren A., Heymach, John V., Coombes, Kevin R., Girard, Luc, Minna, John, You, Ming
Publicado 2012

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy

por Pataer, Apar, Weissferdt, Annikka, Correa, Arlene M., Vaporciyan, Ara A., Sepesi, Boris, Heymach, John V., Berezowska, Sabina, Cascone, Tina, Swisher, Stephen G.
Publicado 2022

TGFβ1 Polymorphisms Predict Distant Metastasis–Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy

por Yuan, Xianglin, Wei, Qingyi, Komaki, Ritsuko, Liu, Zhensheng, Yang, Ju, Tucker, Susan L., Xu, Ting, Heymach, John V., Lu, Charles, Cox, James D., Liao, Zhongxing
Publicado 2013

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

por Lieu, Christopher H., Tran, Hai, Jiang, Zhi-Qin, Mao, Muling, Overman, Michael J., Lin, E., Eng, Cathy, Morris, Jeffrey, Ellis, Lee, Heymach, John V., Kopetz, Scott
Publicado 2013

Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations

por Peng, Shaohua, Sen, Banibrata, Mazumdar, Tuhina, Byers, Lauren A., Diao, Lixia, Wang, Jing, Tong, Pan, Giri, Uma, Heymach, John V., Kadara, Humam N., Johnson, Faye M.
Publicado 2015

Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer

por Gaschler-Markefski, Birgit, Sikken, Patricia, Heymach, John V, Gottfried, Maya, Mellemgaard, Anders, Novello, Silvia, Gann, Claudia-Nanette, Barrueco, José, Reck, Martin, Hanna, Nasser H, Kaiser, Rolf
Publicado 2017

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

por Le, Xiuning, Cornelissen, Robin, Garassino, Marina, Clarke, Jeffrey M., Tchekmedyian, Nishan, Goldman, Jonathan W., Leu, Szu-Yun, Bhat, Gajanan, Lebel, Francois, Heymach, John V., Socinski, Mark A.
Publicado 2022

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

por Lewis, Whitney E., Hong, Lingzhi, Mott, Frank E., Simon, George, Wu, Carol C., Rinsurongkawong, Waree, Lee, J. Jack, Lam, Vincent K., Heymach, John V., Zhang, Jianjun, Le, Xiuning
Publicado 2021

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer

por Thein, Kyaw Z., Biter, Amadeo B., Banks, Kimberly C., Duda, Andrew W., Saam, Jennifer, Roszik, Jason, Janku, Filip, Skoulidis, Ferdinandos, Heymach, John V., Kopetz, Scott, Meric-Bernstam, Funda, Hong, David S.
Publicado 2022

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

por Cardnell, Robert J., Feng, Ying, Mukherjee, Seema, Diao, Lixia, Tong, Pan, Stewart, C. Allison, Masrorpour, Fatemeh, Fan, YouHong, Nilsson, Monique, Shen, Yuqiao, Heymach, John V., Wang, Jing, Byers, Lauren A.
Publicado 2016

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations

por Wang, Yuehong, Singh, Ratnakar, Wang, Liguang, Nilsson, Monique, Goonatilake, Ruchitha, Tong, Pan, Li, Lerong, Giri, Uma, Villalobos, Pamela, Mino, Barbara, Rodriguez-Canales, Jaime, Wistuba, Ignacio, Wang, Jing, Heymach, John V., Johnson, Faye M.
Publicado 2016